NOMOS Corporation’s Peregrine Radiation Dose Calculation System Approved for Marketing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

SEWICKLEY, Pennsylvania-The FDA has granted NOMOS Corporation clearance to market the Peregrine Monte-Carlo-based radiation dose calculation system, licensed from the Lawrence Livermore National Laboratory where it was developed. Peregrine is a computer-based system for quick calculation, in three dimensions, of radiation doses for use with complex intensity-modulated radiotherapy treatment plans. Monte Carlo is a mathematical technique that simulates the trillions of radiation particles that enter the body during treatment. It selects a random sample of these particles and tracks them through a computer model of the radiation-delivery device and the patient’s CT scans to create a detailed map of the dose distribution (see image). NOMOS will initially incorporate Peregrine into its CORVUS inverse treatment planning system, and will then develop a stand-alone version to work with other treatment planning systems.

SEWICKLEY, Pennsylvania—The FDA has granted NOMOS Corporation clearance to market the Peregrine Monte-Carlo-based radiation dose calculation system, licensed from the Lawrence Livermore National Laboratory where it was developed. Peregrine is a computer-based system for quick calculation, in three dimensions, of radiation doses for use with complex intensity-modulated radiotherapy treatment plans. Monte Carlo is a mathematical technique that simulates the trillions of radiation particles that enter the body during treatment. It selects a random sample of these particles and tracks them through a computer model of the radiation-delivery device and the patient’s CT scans to create a detailed map of the dose distribution (see image). NOMOS will initially incorporate Peregrine into its CORVUS inverse treatment planning system, and will then develop a stand-alone version to work with other treatment planning systems.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content